CXCL13 and triple-negative breast carcinoma: Based on Pi analysis, we found that CD4 CXCL13+ showed a significantly positive Pi (P = 0.047; Fig. 5D), consistent with the predictive role of CD4 CXCL13+ in PD-L1 blockade treatment for triple-negative breast cancer (TNBC)18.